Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease

Efficacy of Vedolizumab on Extraintestinal Manifestation in Patients with Inflammatory Bowel Diseases: A Post-Hoc Analysis of the Observ-IBD Cohort of the Getaid

(2017) Sara Tadbiri et al.   GASTROENTEROLOGY

Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study

(2017) Stephan R. Vavricka et al.   INFLAMMATORY BOWEL DISEASES

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

(2017) Fernando Magro et al.   Journal of Crohns & Colitis

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions

(2016) Laurent Peyrin-Biroulet et al.   Clinical Gastroenterology and Hepatology

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

(2016) Fernando Gomollón et al.   Journal of Crohns & Colitis

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

(2015) Hervé Bachelez et al.   LANCET

Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome

(2014) A. V. Marzano et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

(2014) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Biologics for Extraintestinal Manifestations of IBD

(2014) Stephan Vavricka et al.   CURRENT DRUG TARGETS

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence, Mortality, and Disease Associations of Pyoderma Gangrenosum in the United Kingdom: A Retrospective Cohort Study

(2012) Sinéad M. Langan et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE

(2011) Robert Löfberg et al.   INFLAMMATORY BOWEL DISEASES

Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort

(2010) Stephan R Vavricka et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Inflammatory Bowel Disease

(2010) Arthur Kaser et al.   Annual Review of Immunology

Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer

(2010) Manuela Eppenberger et al.   BMC CANCER

Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases

(2010) A. V. Marzano et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

Crohnʼs disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohnʼs disease activity index and endoscopic findings

(2007) Taina Sipponen et al.   INFLAMMATORY BOWEL DISEASES